Phase III and data should be made available this year. Listen to Dr. Berk in his latest conference, he hinted soon. That indicates, sometime this year...and from my understand...Dacogen works best in the advance stages of this cancer. This would probably mean once Vidaza patients crossed over to AML. Dacogen would be the only compound approved for AML and with 50% of MDS patients not taking any of these drugs, well doctors would have to serious look at Dacogen once their patients reached this progression.
I agree with you, but SUPG PPS has a mind of it's own. Favorable data on AML trial would also help the cause and EORTC data needs to be near the 10 month survival benefit. I have been monitoring the MDS foundation boards, looking for signs on how dacogen was holding on to market share....I have not found one single post from actual patients indicating that they had been switched over to vidaza because of survival benefit. I also noticed more new patients to dacogen posting on this board. I believe we will see a jump in January sales of dacogen, specially after the holidays.